Literature DB >> 1644724

Baseline and 2- to 3-year follow-up characteristics of placebo-washout responders from the nortriptyline study of depressed 6- to 12-year-olds.

B Geller1, L W Fox, T B Cooper, K Garrity.   

Abstract

Data are presented on the baseline characteristics and 2- to 3-year follow-up assessments of placebo-washout responders (PWRs) from a previously reported pharmacokinetically designed double-blind placebo-controlled trial of nortriptyline for major depressive disorder in 6- to 12-year-olds. Eleven of the 12 PWRs consented to participate in the follow-up study. At baseline, the only significant difference between the PWRs and the non-PWR subjects was that more females were PWRs. Notably, there were no significant differences with respect to severity, chronicity, age of onset, or comorbid psychopathology. The follow-up assessments showed that the rate of relapse to major depressive disorder and the rate of development of bipolarity were not significantly different for PWRs compared with non-PWRs. The authors discuss these findings vis-à-vis the adult literature and provide recommendations for the use of placebo-washout phases in future double-blind, placebo-controlled psychopharmacology trials in children.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1644724     DOI: 10.1097/00004583-199207000-00008

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  2 in total

1.  Psychopathology in the families of inpatient affective disordered adolescents.

Authors:  C M Borchardt; G A Bernstein; R D Crosby
Journal:  Child Psychiatry Hum Dev       Date:  1995

Review 2.  Are child and adolescent responses to placebo higher in major depression than in anxiety disorders? A systematic review of placebo-controlled trials.

Authors:  David Cohen; Emmanuelle Deniau; Alejandro Maturana; Marie-Laure Tanguy; Nicolas Bodeau; Réal Labelle; Jean-Jacques Breton; Jean-Marc Guile
Journal:  PLoS One       Date:  2008-07-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.